首页>
外国专利>
IMATINIB MESYLATE FOR THE TREATMENT OF NEPHROGENIC SYSTEMIC FIBROSIS
IMATINIB MESYLATE FOR THE TREATMENT OF NEPHROGENIC SYSTEMIC FIBROSIS
展开▼
机译:甲磺酸伊马替尼用于治疗肾性系统性纤维化
展开▼
页面导航
摘要
著录项
相似文献
摘要
Disclosed herein are methods of treatment and/or prevention of nephrogenic systemic fibrosis (NSF) in a subject in need thereof. The methods comprise administering an effective amount of imatinib mesylate to the subject, to thereby treat or prevent the nephrogenic systemic fibrosis. A corticosteroid and/or an antihistamine may also be administered. In one embodiment, the subject has chronic kidney disease, and/or is undergoing hemodialysis, and/or is in renal failure, and/or has been exposed to gadolinium such as gadolinium-containing contrast. The subject may also undergo an additional therapy to treat or prevent nephrogenic systemic fibrosis, chronic kidney disease, or renal failure, such as extracorporeal photopheresis, or administration of pentoxyphyline. Administration may be systemic, such as oral. Useful doses are from about 200 mg-600 mg, a day. Also disclosed are pharmaceutical compositions comprising imatinib mesylate and a pharmaceutically acceptable carrier, optionally formulated for oral administration.
展开▼